Read more here:
Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh